Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-3
Shelf registration
8 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K
Results of Operations and Financial Condition
5 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Oct 23
8-K/A
Submission of Matters to a Vote of Security Holders
14 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 23
8-K
Departure of Directors or Certain Officers
2 Jun 23
ARS
2022 FY
Annual report to shareholders
17 May 23
DEFA14A
Additional proxy soliciting materials
16 May 23
DEF 14A
Definitive proxy
16 May 23
PRE 14A
Preliminary proxy
5 May 23
8-K
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
4 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Apr 23
8-K
Results of Operations and Financial Condition
3 Apr 23
8-K/A
Departure of Directors or Certain Officers
17 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
9 Mar 23
8-K/A
Results of Operations and Financial Condition
17 Jan 23
8-K
Entry into a Material Definitive Agreement
6 Jan 23
8-K
Departure of Directors or Certain Officers
4 Jan 23
8-K
Departure of Directors or Certain Officers
23 Dec 22
8-K
Other Events
12 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
3 Nov 22
8-K
Results of Operations and Financial Condition
3 Oct 22
8-K
Other Events
31 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
9 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 22
Latest ownership filings
4
Robert James Wills
10 Apr 24
4
Robert James Wills
1 Apr 24
4
DAVID F HALE
27 Feb 24
4
Robert James Wills
27 Feb 24
4
JAMES B BREITMEYER
15 Feb 24
4
Chase C. Leavitt
15 Feb 24
4
Rajesh Krishnan
15 Feb 24
4
Salim Yazji
15 Feb 24
4
RICHARD G VINCENT
15 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Rajesh Krishnan
5 Jan 24
4
Salim Yazji
5 Jan 24
4
RICHARD G VINCENT
5 Jan 24
4
Chase C. Leavitt
5 Jan 24
4
JAMES B BREITMEYER
5 Jan 24
4
Chase C. Leavitt
4 Oct 23
4
Salim Yazji
4 Oct 23
4
JAMES B BREITMEYER
4 Oct 23
4
RICHARD G VINCENT
4 Oct 23
4
Rajesh Krishnan
4 Oct 23
4
JAMES B BREITMEYER
5 Jul 23
4
Chase C. Leavitt
5 Jul 23
4
RICHARD G VINCENT
5 Jul 23
4
Salim Yazji
5 Jul 23
4
Rajesh Krishnan
5 Jul 23
4
CHARLES THEUER
30 Jun 23
4
MICHAEL G CARTER
30 Jun 23
4
WILLIAM R LARUE
30 Jun 23
4
Robert James Wills
30 Jun 23
4
ROSEMARY MAZANET
30 Jun 23
4
Xin Nakanishi
30 Jun 23
4
DANIEL L KISNER
30 Jun 23
4
DAVID F HALE
30 Jun 23
4
Jill DeSimone
30 Jun 23
4
Gunnar F. Kaufmann
14 Jun 23
4
JAMES B BREITMEYER
17 Apr 23
4
Salim Yazji
14 Apr 23
4
Chase C. Leavitt
14 Apr 23
4
RICHARD G VINCENT
14 Apr 23
4
JAMES B BREITMEYER
24 Feb 23